Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine
about
Current Advances in Virus-Like Particles as a Vaccination Approach against HIV InfectionNonhuman primate models for HIV/AIDS vaccine developmentChallenges in mucosal HIV vaccine development: lessons from non-human primate modelsA global approach to HIV-1 vaccine developmentLive attenuated Rev-independent Nef¯SIV enhances acquisition of heterologous SIVsmE660 in acutely vaccinated rhesus macaquesShaping T cell - B cell collaboration in the response to human immunodeficiency virus type 1 envelope glycoprotein gp120 by peptide primingAntigenicity, Immunogenicity and Protective Efficacy of Three Proteins Expressed in the Promastigote and Amastigote Stages of Leishmania infantum against Visceral LeishmaniasisDNA-protein immunization using Leishmania peroxidoxin-1 induces a strong CD4+ T cell response and partially protects mice from cutaneous leishmaniasis: role of fusion murine granulocyte-macrophage colony-stimulating factor DNA adjuvantImmunogenicity of DNA vaccines encoding simian immunodeficiency virus antigen targeted to dendritic cells in rhesus macaquesControlling the HIV/AIDS epidemic: current status and global challengesLocal control of repeated-dose rectal challenges in DNA/MVA-vaccinated macaques protected against a first series of simian immunodeficiency virus challenges.Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesCD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challengeThe influence of delivery vectors on HIV vaccine efficacyFcgbp - A Potential Viral Trap in RV144Co-expression of HIV-1 virus-like particles and granulocyte-macrophage colony stimulating factor by GEO-D03 DNA vaccine.Diminished viral control during simian immunodeficiency virus infection is associated with aberrant PD-1hi CD4 T cell enrichment in the lymphoid follicles of the rectal mucosa.DNA/MVA Vaccines for HIV/AIDSAntibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia.Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.No acquisition: a new ambition for HIV vaccine development?What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeysSIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses.Incorporation of a GPI-anchored engineered cytokine as a molecular adjuvant enhances the immunogenicity of HIV VLPs.HIV DNA Vaccine: Stepwise Improvements Make a Difference.Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody.Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.Decreased T Follicular Regulatory Cell/T Follicular Helper Cell (TFH) in Simian Immunodeficiency Virus-Infected Rhesus Macaques May Contribute to Accumulation of TFH in Chronic Infection.Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primatesGag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys.Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive IndividualsBreakthrough Virus Neutralization Resistance as a Correlate of Protection in a Nonhuman Primate Heterologous Simian Immunodeficiency Virus Vaccine Challenge Study.Co-administration of plasmid-encoded granulocyte-macrophage colony-stimulating factor increases human immunodeficiency virus-1 DNA vaccine-induced polyfunctional CD4+ T-cell responses.Relevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination.Signatures in Simian Immunodeficiency Virus SIVsmE660 Envelope gp120 Are Associated with Mucosal Transmission but Not Vaccination Breakthrough in Rhesus MacaquesDNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challengeClinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA
P2860
Q26775082-2D769088-3512-4875-A533-75BD94FBB1CDQ26861148-1A2BE86F-5673-4F1C-A16C-5DE6261281B9Q27022152-9345B8F0-BBDF-401E-A3FD-46FEA6721F88Q27024614-C7ADACB6-F531-417C-B27C-3B6217AD331BQ27305234-32ED5E45-71C4-433F-B059-980D148BFCFBQ27316280-B777F347-3588-4E81-BFE7-9D502474E755Q27318412-6E57EC42-14BB-492F-852A-1529EF2629DDQ28542668-E3BA68B3-67A1-4EFD-8BB9-9B3B38394D1DQ28728563-7FF3DFCC-B318-42FF-8D38-687562C7C3C8Q30420558-BA3BBD24-B270-4819-A016-52E1D17770F4Q33602810-D5E5F366-5BC1-4075-BE5C-D3FB62BF2E6FQ33813145-DAF6626C-3F4C-4D4A-A1B1-0973FA84D6D8Q34059531-14006817-D760-41BE-AAE1-B0BA07081BFBQ34077543-369DC5BF-85F0-41D0-9E12-A85C844576E2Q34201287-243FE07F-9EC1-4749-AA18-75C5E3705EF9Q34309004-443CA6B4-1181-4BE4-B947-DC45396C0CA7Q34364695-028E5AF2-E272-4E14-B6A7-9D1ADE0CA99DQ34492802-6FCCBD35-8130-41EF-AE00-3A922295C3ABQ35105449-6C774D32-E829-4A21-A8A5-C2152028216BQ35129224-9CE2FD50-F27D-4635-B87E-9108F46637D7Q35431516-3637B7A4-4CB0-4330-AAF3-0F0AFDAC0B9AQ35534563-E3CA74D8-A66B-4E65-B6F2-98FBAAE1A9A6Q35641144-026A2D89-8395-4884-BBE6-E1CC0464B3A1Q35729899-F0000867-F9E4-4C82-B9CD-BF3D4E216150Q35754196-1C6478BE-25E0-459E-A471-FF435D7EB521Q35824686-156650F6-D234-4F32-AC1F-3808BADA4AA5Q35826742-188DE58A-FB36-45B6-A044-51B9F8D08798Q35914362-569CA099-E564-437B-8D88-7E4971274CD2Q36007614-F7DBD705-95A5-424F-93E6-F837F42CD45FQ36008380-DF327EFC-07C7-4B6C-B75B-05029AC32804Q36075199-B1185BD2-C0D9-4380-84DD-31AB9B710CBEQ36171855-2D11FC71-FB04-432B-A79C-2302754B7114Q36246220-30C7220F-85E5-4DE4-AD87-659C36DE76AFQ36288468-29B89313-E314-4D32-98E5-A6DF16870D8FQ36334371-462F8622-1E75-4AC1-AE86-32CA533BE398Q36450329-EC65512D-10AC-4BA5-A084-4D88E19EF340Q36474557-C1E97351-A676-43A7-A429-D92C6E729AC2Q36523998-53731E5F-FB62-415B-8A41-5DEE5654024AQ36637349-F8D1557E-2272-4F8C-B0DA-CDD1778D65E7Q36694820-2E5C20CA-8C0B-4FCC-BA65-B7FD8B0B844F
P2860
Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Prevention of infection by a g ...... immunodeficiency virus vaccine
@ast
Prevention of infection by a g ...... immunodeficiency virus vaccine
@en
Prevention of infection by a g ...... immunodeficiency virus vaccine
@nl
type
label
Prevention of infection by a g ...... immunodeficiency virus vaccine
@ast
Prevention of infection by a g ...... immunodeficiency virus vaccine
@en
Prevention of infection by a g ...... immunodeficiency virus vaccine
@nl
prefLabel
Prevention of infection by a g ...... immunodeficiency virus vaccine
@ast
Prevention of infection by a g ...... immunodeficiency virus vaccine
@en
Prevention of infection by a g ...... immunodeficiency virus vaccine
@nl
P2093
P2860
P50
P921
P356
P1476
Prevention of infection by a g ...... immunodeficiency virus vaccine
@en
P2093
Francois Villinger
Harriet L Robinson
Lakshmi Chennareddi
Pamela A Kozlowski
Patricia L Earl
Rama Rao Amara
Suefen Kwa
Vanessa Hirsch
Welkin E Johnson
P2860
P304
P356
10.1093/INFDIS/JIR199
P407
P577
2011-07-01T00:00:00Z